RICCI, ANGELA DALIA
RICCI, ANGELA DALIA
Performance and clinical utility of two targeted multigene panels for GIST molecular characterization
2026 Nannini, M.; Astolfi, A.; Maloberti, T.; Nigro, M. C.; Gozzellino, L.; Costa, A.; Pirini, M. G.; De Leo, A.; Grillini, M.; Altimari, A.; Del Gaudio, M.; Vincenzi, B.; Fumagalli, E.; Brunello, A.; Grignani, G.; Aliberti, S.; Ricci, A. D.; Gelsomino, F.; Setola, E.; Tallini, G.; De Biase, D.; Pantaleo, M. A.
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
2023 Brandi G.; Deiana C.; Galvani L.; Palloni A.; Ricci A.D.; Rizzo A.; Tavolari S.
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
2023 Carloni, R.; Sabbioni, S.; Rizzo, A.; Ricci, A. D.; Palloni, A.; Petrarota, C.; Cusmai, A.; Tavolari, S.; Gadaleta-Caldarola, G.; Brandi, G.
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
2023 Palloni, Andrea; Bisello, Silvia; Maggio, Ilaria; Massucci, Maria; Galuppi, Andrea; Di Federico, Alessandro; Rizzo, Alessandro; Ricci, Angela Dalia; Siepe, Giambattista; Morganti, Alessio Giuseppe; Brandi, Giovanni; Frega, Giorgio
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis
2023 Rizzo, Alessandro; Carloni, Riccardo; Ricci, Angela Dalia; Cusmai, Antonio; Laforgia, Mariarita; Calabrò, Concetta; Ungaro, Valentina; Oreste, Donato; Sollitto, Mario; Palmiotti, Gennaro; Brandi, Giovanni
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study
2022 Ricci, A. D.; Pusceddu, S.; Panzuto, F.; Gelsomino, F.; Massironi, S.; De Angelis, C. G.; Modica, R.; Ricco, G.; Torchio, M.; Rinzivillo, M.; Prinzi, N.; Rizzi, F.; Lamberti, G.; Campana, D.
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
2022 Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G.
Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma
2022 Rizzo A.; Ricci A.D.; Brandi G.
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
2022 Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, Andrea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G.
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
2022 Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi.
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis
2022 Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F.
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
2022 Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G.
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
2022 Rizzo, Alessandro; Carloni, Riccardo; Ricci, Angela Dalia; Di Federico, Alessandro; Guven, Deniz Can; Yalcin, Suayib; Brandi, Giovanni
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data
2022 Ricci A.D.; Rizzo A.; Mollica V.; Schiavina R.; Fiorentino M.; Brunocilla E.; Ardizzoni A.; Massari F.
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
2022 Rizzo, Alessandro; Salati, Massimiliano; Frega, Giorgio; Merz, Valeria; Caputo, Francesco; Di Federico, Alessandro; Palloni, Andrea; Carloni, Riccardo; Ricci, Angela Dalia; Gadaleta-Caldarola, Gennaro; Messina, Carlo; Spallanzani, Andrea; Gelsomino, Fabio; Benatti, Stefania; Luppi, Gabriele; Melisi, Davide; Dominici, Massimo; Brandi, Giovanni
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
2022 Rizzo A.; Ricci A.D.; Cusmai A.; Acquafredda S.; De Palma G.; Brandi G.; Palmiotti G.
Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
2022 Carloni, R.; Rizzo, A.; Ricci, A. D.; Federico, A. D.; De Luca, R.; Guven, D. C.; Yalcin, S.; Brandi, G.
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis
2022 Rizzo A.; Santoni M.; Mollica V.; Ricci A.D.; Calabro C.; Cusmai A.; Gadaleta-Caldarola G.; Palmiotti G.; Massari F.
Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait
2021 Rizzo A.; Ricci A.D.; Brandi G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Performance and clinical utility of two targeted multigene panels for GIST molecular characterization | Nannini, M.; Astolfi, A.; Maloberti, T.; Nigro, M. C.; Gozzellino, L.; Costa, A.; Pirini, M. G.; ...De Leo, A.; Grillini, M.; Altimari, A.; Del Gaudio, M.; Vincenzi, B.; Fumagalli, E.; Brunello, A.; Grignani, G.; Aliberti, S.; Ricci, A. D.; Gelsomino, F.; Setola, E.; Tallini, G.; De Biase, D.; Pantaleo, M. A. | 2026-01-01 | SCIENTIFIC REPORTS | - | 1.01 Articolo in rivista | s41598-025-30548-7.pdf; 41598_2025_30548_MOESM1_ESM.pdf |
| Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue | Brandi G.; Deiana C.; Galvani L.; Palloni A.; Ricci A.D.; Rizzo A.; Tavolari S. | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma.pdf |
| Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma | Carloni, R.; Sabbioni, S.; Rizzo, A.; Ricci, A. D.; Palloni, A.; Petrarota, C.; Cusmai, A.; Tavol...ari, S.; Gadaleta-Caldarola, G.; Brandi, G. | 2023-01-01 | JOURNAL OF HEPATOCELLULAR CARCINOMA | - | 1.01 Articolo in rivista | - |
| The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma | Palloni, Andrea; Bisello, Silvia; Maggio, Ilaria; Massucci, Maria; Galuppi, Andrea; Di Federico, ...Alessandro; Rizzo, Alessandro; Ricci, Angela Dalia; Siepe, Giambattista; Morganti, Alessio Giuseppe; Brandi, Giovanni; Frega, Giorgio | 2023-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | curroncol-30-00358.pdf; curroncol-30-00358-s001.zip |
| Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis | Rizzo, Alessandro; Carloni, Riccardo; Ricci, Angela Dalia; Cusmai, Antonio; Laforgia, Mariarita; ...Calabrò, Concetta; Ungaro, Valentina; Oreste, Donato; Sollitto, Mario; Palmiotti, Gennaro; Brandi, Giovanni | 2023-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study | Ricci, A. D.; Pusceddu, S.; Panzuto, F.; Gelsomino, F.; Massironi, S.; De Angelis, C. G.; Modica,... R.; Ricco, G.; Torchio, M.; Rinzivillo, M.; Prinzi, N.; Rizzi, F.; Lamberti, G.; Campana, D. | 2022-01-01 | JOURNAL OF CLINICAL MEDICINE | - | 1.01 Articolo in rivista | jcm-11-00713-v2.pdf |
| Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials | Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G. | 2022-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma | Rizzo A.; Ricci A.D.; Brandi G. | 2022-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |
| Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? | Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, Giorgio Frega, Alessandro Di Federico, An...drea Palloni, Mariacristina Di Marco, Gennaro Gadaleta-Caldarola, Giovanni Brandi | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavo...lari S.; Di Marco M.; Palloni A.; Brandi G. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | articolo 2022 Immunotherapy in Pancreatic Cancer Why Do We Keep Failing A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.pdf |
| Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes | Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De G...iglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-02429 (1).pdf |
| Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis | Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F. | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? | Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G. | 2022-01-01 | EXPERT OPINION ON INVESTIGATIONAL DRUGS | - | 1.01 Articolo in rivista | - |
| Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis | Rizzo, Alessandro; Carloni, Riccardo; Ricci, Angela Dalia; Di Federico, Alessandro; Guven, Deniz ...Can; Yalcin, Suayib; Brandi, Giovanni | 2022-01-01 | JOURNAL OF PERSONALIZED MEDICINE | - | 1.01 Articolo in rivista | - |
| Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data | Ricci A.D.; Rizzo A.; Mollica V.; Schiavina R.; Fiorentino M.; Brunocilla E.; Ardizzoni A.; Massa...ri F. | 2022-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study | Rizzo, Alessandro; Salati, Massimiliano; Frega, Giorgio; Merz, Valeria; Caputo, Francesco; Di Fed...erico, Alessandro; Palloni, Andrea; Carloni, Riccardo; Ricci, Angela Dalia; Gadaleta-Caldarola, Gennaro; Messina, Carlo; Spallanzani, Andrea; Gelsomino, Fabio; Benatti, Stefania; Luppi, Gabriele; Melisi, Davide; Dominici, Massimo; Brandi, Giovanni | 2022-01-01 | MEDICINA | - | 1.01 Articolo in rivista | - |
| Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future | Rizzo A.; Ricci A.D.; Cusmai A.; Acquafredda S.; De Palma G.; Brandi G.; Palmiotti G. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Systemic Treatment for Metastatic Biliary Tract Cancer.pdf |
| Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine | Carloni, R.; Rizzo, A.; Ricci, A. D.; Federico, A. D.; De Luca, R.; Guven, D. C.; Yalcin, S.; Bra...ndi, G. | 2022-01-01 | TRANSLATIONAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis | Rizzo A.; Santoni M.; Mollica V.; Ricci A.D.; Calabro C.; Cusmai A.; Gadaleta-Caldarola G.; Palmi...otti G.; Massari F. | 2022-01-01 | JOURNAL OF PERSONALIZED MEDICINE | - | 1.01 Articolo in rivista | JPM 2022_[Rizzo PPI].pdf; jpm-12-00842-s001.zip |
| Atezolizumab in advanced hepatocellular carcinoma: Good things come to those who wait | Rizzo A.; Ricci A.D.; Brandi G. | 2021-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |